Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug

Lexicon (LXRX) submits an application to the FDA seeking approval for sotagliflozin to lower the risk of cardiovascular death and hospitalization and urgent visits for heart failure in adult patients.